Skip to main content
. 2014 Feb 13;2014(2):CD008544. doi: 10.1002/14651858.CD008544.pub2

Ralevski 2007.

Trial name or title Topiramate for treatment of patients with borderline personality disorder and alcohol dependence
Methods Randomised placebo‐controlled double‐blind trial
Participants 30 participants
Inclusion criteria: 21 to 60 years old; both genders; diagnosis of alcohol dependence; diagnosis of borderline personality disorder
Exclusion criteria: serious or unstable medical condition; opiate dependence; major Axis I disorder; taking mood stabilisers and antipsychotic medications; liver functional test abnormalities that do not exceed three times normal values
Interventions (1) Topiramate plus SSRI; (2) placebo plus SSRI
Drug dose: topiramate 250 mg/d
Duration: eight weeks. Country of origin: USA
Outcomes Primary outcomes: drinking; craving; aggression
 Secondary outcomes: affect; adverse effects
Starting date March 2007
Contact information Elizabeth Ralevski, PhD, +120 393 25711, ext 4282, elizabeth.ralevski@yale.edu, Yale University, VA Connecticut Healthcare System, West Haven, Connecticut, United States 06516
Notes